Fox Chase researchers have discovered several tumor characteristics that increase the risk of brain metastases in breast cancer patients. These include high-grade tumors, negative progesterone receptor status, and inflammatory breast cancer. The study aims to identify women at risk for brain metastases, potentially leading to preventiv...
Researchers found that levels of a prostate-specific protein up to 18 months after salvage radiation therapy predict mortality and disease progression. Patients with rising PSA levels are at higher risk of spread and death, while those with stable levels may not require immediate hormonal therapy.
Researchers found that younger women (under 35) are more likely to have cancer invade lymph nodes, while a posterior axillary boost reduces regional recurrence rates. The study suggests patients at higher risk may benefit from additional radiation therapy under the armpit.
Researchers at Fox Chase Cancer Center found that precisely targeted radiation therapy is a safe and effective treatment for paranasal sinus cancer, controlling the disease with fewer serious side effects. The study used intensity-modulated radiation therapy (IMRT) to minimize damage to surrounding healthy tissues.
Researchers at Fox Chase Cancer Center found that hypofractionated radiation therapy does not increase urinary or gastrointestinal problems. This new treatment approach delivers a higher total dose of radiation in fewer sessions, without compromising quality of life.
Researchers at Fox Chase Cancer Center found that the loss of protein Nedd9 initially slows cancer formation but then makes tumors more aggressive. A class of drugs already used in clinics can make these aggressive tumors more sensitive to treatment.
Researchers at Fox Chase Cancer Center identified over 60 proteins necessary for cancer cells to survive with EGFR inhibitors, demonstrating a two-hit strategy that increases tumor cell death. This approach will open the door for future therapies and has already led to two clinical trials testing innovative drug combinations.
A team of Fox Chase Cancer Center researchers identified an activation signal for the Aurora-A oncogene, a hyperactive enzyme driving tumor cell proliferation. The discovery may lead to new insights into how cell division is timed and potentially improve treatment options by combining AurA inhibitors with other drugs.
A new treatment regimen combining bevacizumab with standard chemotherapy significantly extends progression-free survival for women with advanced ovarian cancer, reducing disease worsening to 14.1 months compared to 10.3 months. The trial results also point to the possibility of more personalized and effective treatment in the future.
Researchers at Fox Chase Cancer Center are testing a new antibody, MM-111, that targets the HER2/HER3 pathway in patients with advanced breast and gastric cancers. The trial aims to provide an additional therapeutic target within the HER2 pathway and potentially overcome resistance to current HER2-targeted therapies.
A new diagnostic scan using 124I-girentuximab with PET/CT imaging can distinguish between aggressive and less aggressive kidney masses, helping to avoid unnecessary surgeries. The test has a sensitivity and specificity of 86% and 87%, respectively, making it a promising tool for personalized treatment strategies.
Researchers present studies demonstrating progress in using the R.E.N.A.L. Nephrometry Scoring system to standardize surgical decision-making and improve patient outcomes for patients with kidney cancers. The system captures anatomical features of renal masses, allowing for more accurate evaluation of treatment strategies.
Researchers found that smoke triggers rapid changes in gene expression in the lungs of female mice, increasing expression of genes involved in estrogen metabolism. These findings suggest that estrogen metabolism may contribute to lung cancer in non-smoking women.
Researchers found that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, than those who respond least. The study suggests that identifying molecular factors associated with a major pathologic response could lead to important progress in t...
A Phase II trial found that sunitinib was not effective in patients with papillary renal cell carcinoma, highlighting the need for new therapies for this rare subtype of kidney cancer. The study suggests differences in response between clear- and non-clear cell subtypes.
Researchers found that pancreatic cancer patients with circulating tumor cells tend to have worse outcomes, and some types of cells may predict poorer survival. The presence of MUC1 protein-expressing circulating tumor cells is particularly associated with shorter overall survival.
Women who have had a bilateral oophorectomy tend to have smaller tumors and have their tumors detected by mammography rather than physical exam. However, hormone therapy after surgery wipes out any difference in tumor size or detection method.
Research from Fox Chase Cancer Center shows that patients with stage IIIA non-small cell lung cancer (NSCLC) who receive surgery, particularly lobectomy, have increased overall survival rates. This is in contrast to those who received chemoradiation alone.
Fox Chase researchers have discovered that early ovarian cancers arise in inclusion cysts of the ovary. The team found gene expression patterns and extra chromosomes in cells from these cysts compared to normal surface epithelium cells.
Researchers at Fox Chase Cancer Center have found that a new form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block early molecular changes leading to colorectal cancer development while reducing gastrointestinal toxicity. This novel agent may be more effective than standard naproxen in inhibiting tumor growth.
Researchers at Fox Chase Cancer Center have identified NEDD9 as a key molecular player in the formation of HER2-driven breast tumors. The study shows that mice with the Nedd9 gene are more likely to develop tumors over an 18-month period, highlighting the protein's potential as a biomarker.
Researchers at Fox Chase Cancer Center have isolated an engineered antibody, GS45, that targets the Müllerian Inhibiting Substance Type II Receptor on ovarian cancer cells. This unique target is scarce in normal tissue, reducing the risk of side effects associated with traditional targeted therapies.
A new study from Fox Chase Cancer Center suggests that levels of ERCC1 offer a predictive marker of survival in squamous carcinoma of the head and neck. Low ERCC1 levels were associated with increased survival from adjuvant therapy, providing support for personalized medicine in these cancers.
Researchers at Fox Chase Cancer Center found that 15% of clinical trials using terms like erectile dysfunction and hypoactive had exclusionary language for lesbians and gay men. Industry-sponsored trials were more likely to exclude these groups, often due to requiring patients in heterosexual relationships.
Researchers emphasize the need for improved technologies to detect circulating tumor cells (CTC's) due to their metastasizing ability. The current standardized test, CellSearch, has limitations and can only count CTC's, making it essential to explore additional technologies.
Researchers at Fox Chase Cancer Center found that proteosome inhibitors can rescue mutant proteins by increasing levels of Hsp70, a chaperone protein. This approach may be used to treat debilitating genetic diseases, transforming them into more manageable conditions.
Researchers at Fox Chase Cancer Center found that radiation therapy for women with early-stage breast cancer can be shortened from six to seven weeks to four weeks using intensity-modulated radiation therapy (IMRT). The study showed acceptable side effects and similar cure rates and cosmetic results as traditional treatment.
Men with prostate cancer who experience PSA rise within 18 months of radiotherapy are at higher risk of developing spread and dying from their disease. The time between treatment and PSA recurrence has been shown to be a significant predictor of cancer-specific mortality.
Researchers at Fox Chase Cancer Center report an extremely low rate of acute dermatitis and cardiac toxicity when treating HER2-positive breast cancer patients with concurrent Trastuzumab and radiation therapy. The study suggests it may be safe to use both treatments in the adjuvant setting, pending longer follow-up.
A study by Fox Chase Cancer Center researchers found that radiation therapy alone can lead to undetectable PSA levels in patients with prostate cancer. Patients with low PSA scores had less chance of biochemical failure and a higher chance of being cured compared to those with detectable PSA levels.
A recent study published by Fox Chase Cancer Center researchers reveals that nearly a quarter of cancer survivors who still smoke have not been advised to quit by their health care providers in the last year. Health care providers are missing an opportunity to make a significant difference in the quality of life of their patients by no...
Researchers at Fox Chase Cancer Center discovered the Id3 protein plays a crucial role in directing blood cell progenitors to become gamma-delta T cells. These unique cells possess attributes of both the adaptive and innate arms of the immune system, providing enhanced protection against infections and diseases.
Researchers found that NEDD9 protein is required for aggressive breast cancer growth, and its absence limits the appearance of metastatic breast cancer. The study suggests that NEDD9 could serve as a biomarker for aggressive forms of breast cancer.
Researchers at Fox Chase Cancer Center have identified a unique method to inhibit signaling enzymes called kinases using the small molecular inhibitor IPA-3. By targeting PAK1's regulatory domain, IPA-3 is highly selective and takes a more-or-less backdoor approach to shutting down cancer cells.
The Fox Chase-Penn Ovarian SPORE program will focus on three central concepts in ovarian cancer: epigenetics, predictive biomarkers, and targeted therapeutics. The grant will fund five main research projects and three core facilities to support multidisciplinary research efforts.
The Fox Chase Cancer Center has received an $8 million grant to expand its laboratory animal research facility, enabling advanced research into cancer fundamental biological processes. The new facility will house mouse models for cancer research, facilitating the development of new treatments and improving research quality.
Researchers at Fox Chase Cancer Center found that long travel distances to high volume centers pose a barrier to optimal cancer care for some patients. The study showed that increased travel distances were more common among patients with less common cancers, such as esophageal and pancreatic cancer.
A combination of bevacizumab and erlotinib appears to be effective in treating non-small cell lung cancer (NSCLC) in elderly patients, with four partial responses observed. The regimen is well-tolerated, with common side effects including high blood pressure, fatigue, and diarrhea.
Researchers found that patients with second primary lung cancers (SPLC) are more likely to receive surgical treatment and have localized disease at diagnosis compared to those with one primary lung cancer (OPLC). However, SPLC patients experience a 12% higher lung cancer-specific mortality rate.
Researchers at Fox Chase Cancer Center have found that lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib. The study suggests that patients who are no longer controlled by cetuximab can derive clinical benefit from erlotinib, offering an additional treatment option.
Fox Chase researchers found that DLX5 promotes cancer by activating the expression of MYC, a potent factor in numerous cancers. The discovery suggests that DLX5 could be an ideal target for future anti-cancer drugs.
A study of 577 breast cancer patients found that routine use of MRI scans was associated with delays in starting treatment and increased mastectomy rates. The study suggests that more research is needed to determine the benefits of MRI scans in evaluating breast cancer, as their disadvantages may outweigh any potential advantages.
A phase I trial found a two-drug combination of temsirolimus and bryostatin to be safe and active in patients with metastatic kidney cancer. The combination showed sustained responses in some patients, particularly those with rare forms of renal cell carcinoma that don't respond well to standard therapies.
In a phase I/II trial, combining trastuzumab and neratinib induced clinically meaningful responses in women with HER2-positive metastatic breast cancer who had progressed on previous trastuzumab-based therapies. Nine out of 33 patients (27%) achieved an objective response to the combination therapy.
A study by Fox Chase Cancer Center researchers reveals that 'disordered' amino acids in the signaling protein NHERF1 enable flexibility and molecular switching. This finding challenges traditional views on the role of disordered sequences in proteins.
Cancer care's high costs are impacting patients' welfare and society as a whole. The economic burden is too great to ignore, with rising costs threatening personalized medicine's promise.
Researchers have identified a genetic marker associated with an earlier onset of prostate cancer in high-risk men. The Met160Val SNP is linked to a 2.5-fold increased risk of developing prostate cancer, and carriers are more likely to develop the disease earlier.
Researchers at Fox Chase Cancer Center found that low-oxygen regions in prostate tumors are associated with increased PSA levels, a marker of tumor recurrence. The study used a custom-built probe to monitor oxygen levels in tumors and non-cancerous muscle tissue before localized radiation therapy.
Researchers at Fox Chase Cancer Center have discovered a genetic pattern that can help predict how patients with gastrointestinal stromal tumors respond to the targeted therapy imatinib mesylate. By analyzing tumor specimens, they found genes that could be suppressed to enhance the effectiveness of imatinib therapy.
A recent study at Fox Chase Cancer Center found that most parents share their BRCA1/2 test results with their children, with only 9% reporting negative reactions. The age of the child and parent cancer history were key factors in determining whether or not to share the results.